RESUMEN
There have been 6-10 million reported patients with chronic hepatitis B virus (HBV) infection worldwide, and the United Nations (UN) called for a "90% reduction by 2030" strategy. Since the wide practice of HBV vaccination, the numbers of HBV cases have been reduced by 85% and the incidence of hepatocellular carcinoma has also decreased by 50%. As formulated by the UN in 2015, the sustainable development agenda for the eradication of hepatitis B included the success rate of preventing mother-to-child viral transmission by 95%, together with the reduction of new hepatitis B infections by 90% in 2030. In order to achieve the agenda, we proposed a strategy to achieve the "three 96%" goals derived from the Shanghai experience. In brief, hepatitis B vaccine should cover for 96% newborns within 24 h, and the vaccination boosting rate should reach 96% for both one and six months after birth. If cutting off the mother-to-child viral transmission strategy can be successfully achieved, the future of hepatitis B prevention will be promising, and the task of eliminating hepatitis B and controlling hepatocellular carcinoma can be completed ahead of 2030, time proposed by the UN.
RESUMEN
Objective:To understand the efficacy of gene hepatitis B vaccine associated with hepatitis B immune globulin on interrupting the mather-infant transmission of HBV and to explore the most effective immunotherapy plan.Methods:A total of 99 cases of HBsAg-positive pregnant women were chosen as investigation objects,which were then divided into test and control groups by various testing period.According to the different vaccination ways of hepatitis B vaccine,test groups were divided into Group A(muscular injection way)and Group B(intradermal injection way).Pregnant women in the test groups were intramuscularly injected with HBIG of 200IU at week 28,32 and 36 of gestation;the neonates were intramuscularly injected with HBIG of 200IU at postnatal 4 h,and on the 15th and 30th day and vaccinated gene Hepatitis B vaccine of 5 ?g at birth date,a month and six months after birth respectively.Control group were routinely inoculated by hepatitis B vaccine.HBsAg and anti-HBs in the serum were monitored by following-up the children for five years.Results:The blocking rate of mother-infant transmission of HBV in test group was 98.36%,however,the blocking rate of control group was 83.33%(P0.05).The blocking rate in HBeAg and HBsAg-positive group was 77.78%,but,in HBsAg-positive group,the blocking rate was 97.26%(P